Plasma Concentration, Excretion and Mass Balance Orally Administered 14C-FYU-981 in Healthy Male Subjects

Trial Profile

Plasma Concentration, Excretion and Mass Balance Orally Administered 14C-FYU-981 in Healthy Male Subjects

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs FYU-981 (Primary)
  • Indications Hyperuricaemia
  • Focus Pharmacokinetics
  • Sponsors Fuji Yakuhin
  • Most Recent Events

    • 01 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.
    • 04 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Oct 2017.
    • 04 Apr 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top